Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
04:09pm, Tuesday, 19'th Nov 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Marion McCourt
Regeneron: The Biotech Stock To Buy Now
03:52pm, Tuesday, 19'th Nov 2024
Biotech stocks, including Regeneron, have seen significant declines due to regulatory and political uncertainty, presenting a potential buying opportunity as seller exhaustion nears. Regeneron's 40% d
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
04:01pm, Monday, 18'th Nov 2024
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
01:40pm, Friday, 15'th Nov 2024
The Investment Committee give you their top stocks to watch for the second half.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
01:00am, Friday, 15'th Nov 2024
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
12:59am, Friday, 15'th Nov 2024
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antih
2 Top Growth Stocks to Buy on the Dip
07:00am, Thursday, 14'th Nov 2024
Their recent issues are nothing to fret over for investors focused on the long game.
Regeneron initiated with a Neutral at Citi
04:15pm, Wednesday, 13'th Nov 2024
Citi initiated coverage of Regeneron with a Neutral rating and $895 price target. Multiple clinical data readouts should "keep investors engaged" over the next 12-24 months and while Eylea-HD, or high
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
07:00am, Wednesday, 13'th Nov 2024
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
Regeneron Announces Investor Conference Presentations
04:05pm, Monday, 11'th Nov 2024
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
09:37am, Wednesday, 06'th Nov 2024
When thinking about stocks with recession-resistant characteristics, a few key metrics come to mind. First are low-beta stocks.
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
04:11am, Wednesday, 06'th Nov 2024
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
01:00am, Wednesday, 06'th Nov 2024
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
01:00am, Wednesday, 06'th Nov 2024
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on D
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Regeneron Pha
